Dr. Allison Bock, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- Medical College of Wisconsin (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 86
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: Medical College of Wisconsin
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
UT license 13278691-1205 -
Hematology & Oncology Physician
MN license 67073
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Utah Hospital and Clinics Salt Lake City, UT
Medical groups
- University of Utah Adult Services (1,788 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 86
- Services billed
- 733
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 119 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 39 | 28 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Rochester, MN | 42 |
| Prednisone Other prescribers in Rochester, MN | 38 |
| Calquence (acalabrutinib maleate) | 24 |
| Levofloxacin Other prescribers in Rochester, MN | 24 |
| Ondansetron Hcl Other prescribers in Rochester, MN | 17 |
| Prochlorperazine Maleate Other prescribers in Rochester, MN | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 12 payments worth $6,743 in total to this clinician.
| AbbVie Inc. | $3,037 |
|---|---|
| Incyte Corporation | $1,650 |
| Genmab U.S., Inc. | $1,455 |
| Beone Medicines USA, Inc. | $301 |
| AstraZeneca Pharmaceuticals LP | $135 |
| Adc Therapeutics America, Inc. | $91.04 |
| Genentech USA, Inc. | $74.16 |
| Compensation for services other than consulting (speaking, faculty) | $4,313 |
|---|---|
| Consulting Fee | $1,650 |
| Food and Beverage | $646 |
| Travel and Lodging | $134 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. May 16, 2025 | Compensation for services other than consulting (speaking, faculty) EPKINLY · ONCOLOGY | $3,000 |
| Incyte Corporation Jul 24, 2025 | Consulting Fee | $1,650 |
| Genmab U.S., Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) Epkinly · Oncology | $1,313 |
| Beone Medicines USA, Inc. Dec 5, 2025 | Travel and Lodging BRUKINSA · Oncology · travel to Orlando, FL · in-kind | $119 |
| Genmab U.S., Inc. Oct 8, 2025 | Travel and Lodging Epkinly · Oncology · travel to Salt Lake City, UT | $15.40 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $83,908 in research payments for these studies, mostly to the institutions running them.
- A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06091254
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.